PharmEasy-Owned Thyrocare Q2 Profit rises 81% YoY to INR 48 crore in Q2 FY26, driven by strong pathology growth, margin gains, and record test volumes. Learn how KuberGrow tracks such market leaders in the unlisted and listed space.
PharmEasy-Owned Thyrocare Q2 Profit rises 81% YoY to INR 48 crore in Q2 FY26, driven by strong pathology growth, margin gains, and record test volumes. Learn how KuberGrow tracks such market leaders in the unlisted and listed space.